Since the SMN2 copy number is the primary genetic modifier of disease severity, several therapeutic approaches for SMA have focused on increasing expression of SMN through modulation of SMN2 exon 7 splicing [4,5,6]. Here, SMN2 is linked to proximal spinal muscular atrophy.